1. 竺可桢杰出学者系列讲座(17-1): Sphingolipid metabolism (鞘脂类代谢)
报告人：Prof. Yusuf A. Hannun, Director, Stony Brook Cancer Center, Vice Dean for Cancer Medicine, Joel Kenny Professor of Medicine.
2. Bioactive sphingolipids in cell growth (细胞生长过程中的活性鞘脂类分子)
报告人：Prof. Lina M. Obeid, Stony Brook Cancer Center, Department of Medicine, Dean for Research and Professor of Medicine.
3. Roles for alkaline ceramidases in regulating sphingolipid metabolism and signaling (碱性神经酰胺酶在调控鞘脂类代谢和信号转导中的作用).
报告人：Prof. Cungui Mao, Stony Brook Cancer Center, Department of Medicine.
时间：2013年5月06日（周一）9:00~12:00
地点：浙江大学紫荆港校区农生环组团C座1012
欢迎各位师生踊跃参加！
报告人简介：
Dr. Yusuf A. Hannun, a renowned molecular biologist and physician-scientist investigating the molecular mechanisms of cancer.
As director of the Stony Brook Cancer Center, Dr. Hannun will oversee several multidisciplinary disease management teams for all types of cancers, and will be a key player in the Cancer Center achieving NCI Cancer Center designation.
The recruitment of Dr. Yusuf Hannun as Stony Brook’s new Cancer Center director, and further investment in faculty recruitment—along with physically bringing cancer clinical services and research laboratories together in a true Cancer Center located in the new Medical and Research Translation (MART)- will position Stony Brook to obtain the prestigious designation of a National Cancer Institute from the National Institutes of Health (NIH).
Dr. Lina Obeid, a physician-scientist and biomedical researcher, has been appointed dean for research and professor of medicine at Stony Brook School of Medicine. She comes to Stony Brook from the Medical University of South Carolina (MUSC). At Stony Brook she will oversee the Office of Scientific Affairs (OSA), which facilitates the biomedical research enterprise of Stony Brook Medicine and involves scientists engaged in all aspects of basic, translational and clinical research discoveries.
Dr. Cungui Mao, and his team have engaged in groundbreaking lipid research for the past 10 years. They were the first, for example, to identify and clone three human alkaline ceramidases (ACER1, ACER2 and ACER3). These enzymes, which are made in different tissues, can induce tumor cell death and inhibit cell division or do the opposite — making them ideal subjects for potential new cancer therapies.
Recently, Dr. Mao and his team of five full-time researchers moved their research program to the Division of Cancer Prevention at Stony Brook University Cancer Center from the Hollings Cancer Center in South Carolina. With them comes a five-year grant from the NCI (preceded by a five-year NIH grant) to fund the research. “Their hope with this novel research is to find new approaches and compounds to treat cancers and perhaps enhance or perfect chemotherapy drugs,” says Dr. Mao. “Because the expression of these enzymes is altered in skin cancer and colon cancer, these might be the first areas for which the research might be applicable. However, at present, we are still working with cell cultures and animal models. A major goal is to see if normalizing the expression of these enzymes in cancer cells can inhibit tumor growth.”
